



Final Appraisal Recommendation

Advice No: 1212 – June 2012

Rifaximin (Xifaxanta[®]▼) 200 mg film-coated tablets

Limited submission by Norgine Pharmaceuticals Ltd

Recommendation of AWMSG

Rifaximin (Xifaxanta[®]▼) is recommended as an option for use within NHS Wales for the treatment of travellers' diarrhoea that is not associated with any of: fever, bloody diarrhoea, eight or more unformed stools in the previous 24 hours, occult blood or leucocytes in the stool or to shorten the duration of diarrhoea when this is associated with non-invasive strains of *E. coli*.

Additional note:

- AWMSG are of the opinion that rifaximin (Xifaxanta[®]▼) may be appropriate for prescribing by all prescribers within NHS Wales for the above indication.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report (ASAR), the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), lay perspective (where available) and discussions at AWMSG.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Norgine Pharmaceuticals Ltd
Date of first issue	June 2012
Last reviewed	August 2016

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1212:
Rifaximin (Xifaxanta[®]▼) 200 mg film-coated tablets. June 2012.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.